Dougald M Monroe

List of Publications by Year
in descending order

169 papers	10,501 citations	50566 48 h-index	37326 100 g-index
172 all docs	172 docs citations	172 times ranked	7089 citing authors

#	Article	IF	Citations
1	Computationally Driven Discovery in Coagulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 79-86.	1.1	4
2	The Art and Science of Building a Computational Model to Understand Hemostasis. Seminars in Thrombosis and Hemostasis, 2021, 47, 129-138.	1.5	11
3	Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. Nature Communications, 2021, 12, 6912.	5.8	6
4	Emizicumab Promotes Factor Xa Generation on Activated Endothelium in a Blood Cell-Independent Manner. Blood, 2021, 138, 3182-3182.	0.6	0
5	Excessive breakthrough bleeding in haemophilia B patients on factor IXâ€albumin fusion protein prophylactic therapy: A single centre case series. Haemophilia, 2020, 26, e23-e25.	1.0	13
6	Protease: Serpin complexes to assess contact system and intrinsic pathway activation. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 789-798.	1.0	8
7	Platelet-like particles improve fibrin network properties in a hemophilic model of provisional matrix structural defects. Journal of Colloid and Interface Science, 2020, 577, 406-418.	5.0	8
8	EPCR knockout: inflaming the discussion. Blood, 2020, 135, 2201-2202.	0.6	0
9	VWF (von Willebrand Factor) Is Not Required for Red Blood Cell Retention in Clots in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1952-1954.	1.1	1
10	Mouse models of hemostasis. Platelets, 2020, 31, 417-422.	1.1	31
11	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood, 2020, 135, 755-765.	0.6	61
12	In Hemophilia Î˚ Plasma Treated with Emicizumab, Factor IX Activation By Factor VIIa Drives Thrombin Generation. Blood, 2020, 136, 17-17.	0.6	0
13	In Hemophilia Î˚ Plasma Treated with Emicizumab, Factor IXa in Activated Prothrombin Complex Concentrates Is the Dominant Contributor to Enhanced Thrombin Generation. Blood, 2020, 136, 16-17.	0.6	0
14	Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies. Scientific Reports, 2019, 9, 15449.	1.6	38
15	A unique protein kinaseÂCâ€dependent pathway for tissue factor downregulation in pericytes. Journal of Thrombosis and Haemostasis, 2019, 17, 670-680.	1.9	0
16	Assessing the impact of product inhibition in a chromogenic assay. Analytical Biochemistry, 2019, 580, 62-71.	1.1	2
17	Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis. Blood, 2019, 134, 3623-3623.	0.6	0
18	Harold Ross Roberts, <scp>MD</scp>, 1930â€2017. Haemophilia, 2018, 24, 13-14.	1.0	0

#	Article	IF	Citations
19	In vitro characterization of <scp>MOD</scp>â€5014, a novel longâ€acting carboxyâ€terminal peptide (CTP)â€modified activated FVII. Haemophilia, 2018, 24, 477-486.	1.0	16
20	FactorÂXI promotes hemostasis in factorÂIXâ€deficient mice. Journal of Thrombosis and Haemostasis, 2018, 16, 2044-2049.	1.9	16
21	Abstract 288: Nitric Oxide Mediates Active Downregulation of Tissue Factor Expression in Human Pericytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	1.1	1
22	Biochemical Characteristics of Emicizumab Activity with Factors IXa, X, and VIIa. Blood, 2018, 132, 1167-1167.	0.6	3
23	Histones Induce the Release of Extracellular Hemoglobin and Red Blood Cell-Derived Microvesicles with Procoagulant Activity. Blood, 2018, 132, 2514-2514.	0.6	2
24	Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B. Journal of Medical Genetics, 2017, 54, 338-345.	1.5	66
25	Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. Blood, 2017, 129, 2161-2171.	0.6	40
26	In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood, 2017, 129, 1021-1029.	0.6	183
27	Impact of Nonâ€“Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1812-1818.	1.1	15
28	Characterization of IXINITYÂ® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph. Advances in Hematology, 2016, 2016, 1-9.	0.6	12
29	Coated platelet assay: a feasible approach to a complicated science. Haemophilia, 2016, 22, e67-e70.	1.0	1
30	Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?. Haemophilia, 2016, 22, 148-151.	1.0	7
31	A novel one-step purification of mouse factor IX. Thrombosis Research, 2016, 139, 125-126.	0.8	4
32	Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice. Blood, 2016, 128, 286-292.	0.6	44
33	Thrombin generation and cellâ€dependent hypercoagulability in sickle cell disease. Journal of Thrombosis and Haemostasis, 2016, 14, 1941-1952.	1.9	53
34	Adding some muscle to blood coagulation. Blood, 2016, 128, 1786-1787.	0.6	5
35	Anticoagulation increases alveolar hemorrhage in mice infected with influenza A. Physiological Reports, 2016, 4, e13071.	0.7	16
36	An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model. Journal of Thrombosis and Haemostasis, 2016, 14, 1249-1254.	1.9	2

#	Article	IF	Citations
37	Polyphosphates rock! A role in thrombosis?. Blood, 2015, 126, 1403-1404.	0.6	1
38	Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate. Anesthesiology, 2015, 122, 353-362.	1.3	27
39	Cystamine Preparations Exhibit Anticoagulant Activity. PLoS ONE, 2015, 10, e0124448.	1.1	10
40	Novel mouse hemostasis model for realâ€time determination of bleeding time and hemostatic plug composition. Journal of Thrombosis and Haemostasis, 2015, 13, 417-425.	1.9	61
41	Purified DNA, but Not Neutrophil Extracellular Traps (NETs), Promotes Contact Activation of Coagulation. Blood, 2015, 126, 767-767.	0.6	0
42	Soluble Phosphatidylserine Binds to Two Sites on Human Factor IXa in a Ca2+ Dependent Fashion to Specifically Regulate Structure and Activity. PLoS ONE, 2014, 9, e100006.	1.1	5
43	Reversing targeted oral anticoagulants. Hematology American Society of Hematology Education Program, 2014, 2014, 518-523.	0.9	4
44	A mouse bleeding model to study oral anticoagulants. Thrombosis Research, 2014, 133, S6-S8.	0.8	16
45	FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood, 2014, 123, 1764-1766.	0.6	31
46	Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood, 2014, 123, 1747-1756.	0.6	98
47	Plasmin Activation of Glial Cells through Protease-Activated Receptor 1. Pathology Research International, 2013, 2013, 1-8.	1.4	6
48	Progressive improvement in wound healing with increased therapy in haemophilia B mice. Haemophilia, 2013, 19, 926-932.	1.0	8
49	Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. Journal of Thrombosis and Haemostasis, 2013, 11, 1043-1052.	1.9	23
50	Superactivated Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1747-1752.	1.1	71
51	Major burn injury is not associated with acute traumatic coagulopathy. Journal of Trauma and Acute Care Surgery, 2013, 74, 1474-1479.	1.1	41
52	Reversal Of Dabigatran Anticoagulation By a 4-Factor Prothrombin Complex Concentrate: Correlation Between Effects On Parameters Of Thrombin Generation and Hemostatic Effect In Vivo. Blood, 2013, 122, 3643-3643.	0.6	1
53	Downregulation Of Tissue Factor Expression In Human Pericytes In An Endothelial Cell Co-Culture Model. Blood, 2013, 122, 3524-3524.	0.6	0
54	Potent Anticoagulant Aptamer Directed against Factor IXa Blocks Macromolecular Substrate Interaction. Journal of Biological Chemistry, 2012, 287, 12779-12786.	1.6	28

#	Article	IF	Citations
55	Factor VIIa: on its own and loving it. Blood, 2012, 120, 705-707.	0.6	5
56	Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity. Wound Repair and Regeneration, 2012, 20, 770-777.	1.5	19
57	Studies on the mechanism of action of the aptamer BAX499, an Inhibitor of tissue factor pathway inhibitor. Thrombosis Research, 2012, 130, e151-e157.	0.8	22
58	The multiple roles of tissue factor in wound healing. Frontiers in Bioscience - Scholar, 2012, S4, 713-721.	0.8	6
59	Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thrombosis and Haemostasis, 2012, 107, 717-725.	1.8	27
60	Models for assessing immunogenicity and efficacy of new therapeutics for the treatment of haemophilia. Haemophilia, 2012, 18, 43-47.	1.0	9
61	The clotting system â€“ a major player in wound healing. Haemophilia, 2012, 18, 11-16.	1.0	39
62	A high affinity, antidoteâ€controllable prothrombin and thrombinâ€binding RNA aptamer inhibits thrombin generation and thrombin activity. Journal of Thrombosis and Haemostasis, 2012, 10, 870-880.	1.9	57
63	Partial Reversal of Dabigatran Effect by a Prothrombin Complex Concentrate in a Model of Thrombin Generation. Blood, 2012, 120, 3420-3420.	0.6	5
64	Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. Journal of Thrombosis and Haemostasis, 2011, 9, 759-766.	1.9	22
65	The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation. Blood, 2011, 118, 541-541.	0.6	0
66	Inflammation does not predispose to bleeding in hemophilia. Journal of Thrombosis and Haemostasis, 2010, 8, 2583-2585.	1.9	4
67	Wound healing in haemophilia â€“ breaking the vicious cycle. Haemophilia, 2010, 16, 13-18.	1.0	31
68	An Anticoagulant RNA Aptamer That Inhibits Proteinase-Cofactor Interactions within Prothrombinase. Journal of Biological Chemistry, 2010, 285, 5212-5223.	1.6	42
69	Activation of Protease-Activated Receptors 3 and 4 Accelerates Tissue Factorâ€“Induced Thrombin Generation on the Surface of Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2587-2596.	1.1	14
70	Platelet binding and activity of recombinant factor VIIa. Thrombosis Research, 2010, 125, S16-S18.	0.8	13
71	Wound healing in hemophilia B mice and low tissue factor mice. Thrombosis Research, 2010, 125, S74-S77.	0.8	24
72	Increased Platelet Binding of NN1731, a Factor VIIa Variant with Enhanced Tissue Factor-Independent Activity.. Blood, 2010, 116, 1133-1133.	0.6	0

#	Article	IF	Citations
73	What Is Wrong With the Allosteric Disulfide Bond Hypothesis?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1997-1998.	1.1	25
74	Tissue Factor in Brain Is Not Saturated With Factor VIIa. Stroke, 2009, 40, 2882-2884.	1.0	27
75	A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation. Journal of Thrombosis and Thrombolysis, 2009, 28, 132-139.	1.0	6
76	Celecoxib does not delay cutaneous wound healing in haemophilia B mice. Haemophilia, 2009, 15, 615-616.	1.0	4
77	Abnormal hemostasis in a knockâ€in mouse carrying a variant of factorÂIX with impaired binding to collagen typeÂIV. Journal of Thrombosis and Haemostasis, 2009, 7, 1843-1851.	1.9	48
78	The Coagulation Cascade in Cirrhosis. Clinics in Liver Disease, 2009, 13, 1-9.	1.0	62
79	Dysregulation of Hemostasis by Cancer. Cancer Treatment and Research, 2009, 148, 3-15.	0.2	3
80	Platelet activation and its patient-specific consequences. Thrombosis Research, 2008, 122, 435-441.	0.8	6
81	Further Understanding of Recombinant Activated Factor VII Mode of Action. Seminars in Hematology, 2008, 45, S7-S11.	1.8	22
82	Modeling the action of factor VIIa in dilutional coagulopathy. Thrombosis Research, 2008, 122, S7-S10.	0.8	21
83	Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia. Blood, 2008, 111, 2046-2048.	0.6	31
84	Clinical Role of Recombinant Factor VIIa in Bleeding Disorders. , 2008, , 587-596.		0
85	Coagulation 2006: A Modern View of Hemostasis. Hematology/Oncology Clinics of North America, 2007, 21, 1-11.	0.9	219
86	Fathers of modern coagulation. Thrombosis and Haemostasis, 2007, 98, 3-5.	1.8	9
87	The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. Journal of Thrombosis and Haemostasis, 2007, 5, 1097-1105.	1.9	130
88	Tissue factor around dermal vessels has bound factor VII in the absence of injury. Journal of Thrombosis and Haemostasis, 2007, 5, 1403-1408.	1.9	77
89	Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. Journal of Thrombosis and Haemostasis, 2007, 5, 1577-1583.	1.9	44
90	Role of Gamma-Carboxyglutamic Acid (GLA) Domain in Phosphatidylserine (PS)-Regulated Activity of Factor IXa.. Blood, 2007, 110, 2696-2696.	0.6	3

#	Article	IF	Citations
91	What Does It Take to Make the Perfect Clot?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 41-48.	1.1	341
92	Cutaneous wound healing is impaired in hemophilia B. Blood, 2006, 108, 3053-3060.	0.6	104
93	Thrombin generation in vascular tissue. Journal of Thrombosis and Haemostasis, 2006, 4, 60-67.	1.9	11
94	Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. Journal of Thrombosis and Haemostasis, 2006, 4, 2092-2093.	1.9	49
95	Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. British Journal of Haematology, 2006, 134, 314-319.	1.2	36
96	A Cell-Based Model of Thrombin Generation. Seminars in Thrombosis and Hemostasis, 2006, 32, 032-038.	1.5	195
97	Recombinant activated factor VII and the anaesthetist.. Anaesthesia, 2005, 60, 1203-1212.	1.8	27
98	High dose factor VIIa improves clot structure and stability in a model of haemophilia B. British Journal of Haematology, 2005, 131, 645-655.	1.2	127
99	Rethinking the Coagulation Cascade. Japanese Journal of Thrombosis and Hemostasis, 2005, 16, 70-81.	0.1	28
100	Platelet Heterogeneity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 861-866.	1.1	89
101	Delayed Wound Healing in Hemophilia B Mice.. Blood, 2005, 106, 3199-3199.	0.6	1
102	Rethinking the coagulation cascade. Psychophysiology, 2005, 4, 391-6.	1.1	33
103	Role of the Î³-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin. Journal of Thrombosis and Haemostasis, 2004, 2, 1127-1134.	1.9	7
104	Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. Journal of Thrombosis and Haemostasis, 2004, 2, 1816-1822.	1.9	47
105	Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. Journal of Thrombosis and Haemostasis, 2004, 2, 402-413.	1.9	153
106	Safety profile of recombinant factor VIIa. Seminars in Hematology, 2004, 41, 101-108.	1.8	170
107	A Systematic Evaluation of the Effect of Temperature on Coagulation Enzyme Activity and Platelet Function. Journal of Trauma, 2004, 56, 1221-1228.	2.3	424
108	More Information on Patients with Factor XI Deficiency. Anesthesiology, 2004, 101, 1253-1254.	1.3	0

#	Article	IF	Citations
109	Current Concepts of Hemostasis. Anesthesiology, 2004, 100, 722-730.	1.3	130
110	The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood, 2004, 104, 3858-3864.	0.6	259
111	Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood, 2003, 101, 3008-3013.	0.6	145
112	Mechanism of Action of High-Dose Factor VIIa. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 8-9.	1.1	33
113	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	0.4	20
114	The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients. Journal of Trauma, 2003, 55, 886-891.	2.3	415
115	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	0.4	30
116	Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood, 2002, 100, 539-546.	0.6	49
117	Platelets and Thrombin Generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1381-1389.	1.1	579
118	RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 2002, 419, 90-94.	13.7	492
119	Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Canadian Journal of Anaesthesia, 2002, 49, S7-14.	0.7	25
120	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Seminars in Hematology, 2001, 38, 6-9.	1.8	76
121	A Cell-based Model of Hemostasis. Thrombosis and Haemostasis, 2001, 85, 958-965.	1.8	1,286
122	High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. British Journal of Haematology, 2001, 114, 114-120.	1.2	126
123	A cell-based model of hemostasis. Thrombosis and Haemostasis, 2001, 85, 958-65.	1.8	348
124	The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagulation and Fibrinolysis, 2000, 11, S3-S7.	0.5	38
125	Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. American Journal of Hematology, 2000, 65, 30-34.	2.0	112
126	Links Between the Immune and Coagulation Systems: How Do "Antiphospholipid Antibodies" Cause Thrombosis?. Immunologic Research, 2000, 22, 191-198.	1.3	14

#	Article	IF	Citations
127	The Factor VII-Platelet Interplay: Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Severe Thrombocytopathia. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 0373-0378.	1.5	87
128	Deencryption of Cellular Tissue Factor Is Independent of Its Cytoplasmic Domain. Biochemical and Biophysical Research Communications, 2000, 272, 332-336.	1.0	38
129	Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. , 2000, 65, 30.		5
130	TFPIÎ², a Second Product from the Mouse Tissue Factor Pathway Inhibitor (TFPI) Gene. Thrombosis and Haemostasis, 1999, 81, 45-49.	1.8	56
131	Thrombin Activates Factor XI on Activated Platelets in the Absence of Factor XII. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 170-177.	1.1	169
132	Tissue factor de-encryption. Blood Coagulation and Fibrinolysis, 1999, 10, 201-210.	0.5	92
133	Newer concepts of blood coagulation. Haemophilia, 1998, 4, 331-334.	1.0	100
134	Structure/Function Analyses of Recombinant Variants of Human Factor Xa:â€‰ Factor Xa Incorporation into Prothrombinase on the Thrombin-Activated Platelet Surface Is Not Mimicked by Synthetic Phospholipid Vesicles. Biochemistry, 1998, 37, 5029-5038.	1.2	50
135	Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thrombosis and Haemostasis, 1998, 80, 578-84.	1.8	33
136	A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagulation and Fibrinolysis, 1998, 9 Suppl 1, S15-20.	0.5	20
137	Arginine 200 of Heparin Cofactor II Promotes Intramolecular Interactions of the Acidic Domain. Journal of Biological Chemistry, 1997, 272, 14074-14079.	1.6	12
138	Platelet activity of high-dose factor VIIa is independent of tissue factor. British Journal of Haematology, 1997, 99, 542-547.	1.2	557
139	The Effect of Active Site-inhibited Factor VIIa on Tissue Factor-initiated Coagulation Using Platelets before and after Aspirin Administration. Thrombosis and Haemostasis, 1997, 78, 1202-1208.	1.8	18
140	Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.. Journal of Clinical Investigation, 1997, 100, 886-892.	3.9	38
141	Variability in platelet procoagulant activity in healthy volunteers. Thrombosis Research, 1996, 81, 533-543.	0.8	68
142	Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagulation and Fibrinolysis, 1996, 7, 459-464.	0.5	100
143	Cellular Interactions in Hemostasis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 12-16.	0.5	22
144	Structural Integrity of the Î³-Carboxyglutamic Acid Domain of Human Blood Coagulation Factor IXa Is Required for Its Binding to Cofactor VIIIa. Journal of Biological Chemistry, 1996, 271, 3869-3876.	1.6	51

#	Article	IF	Citations
145	Characterization of the Glycosaminoglycan-Binding Region of Lactoferrin. Archives of Biochemistry and Biophysics, 1995, 317, 85-92.	1.4	99
146	Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 1995, 86, 1794-801.	0.6	33
147	Prothrombin times on deficient plasma reconstituted with factors IX and X. American Journal of Hematology, 1994, 47, 246-246.	2.0	0
148	Platelet procoagulant complex assembly in a tissue factor-initiated system. British Journal of Haematology, 1994, 88, 364-371.	1.2	99
149	Platelet activation in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, 1993, 42, 182-185.	2.0	14
150	Comparison of the behavior of normal factor IX and the factor IX BM variant hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources. American Journal of Hematology, 1993, 43, 177-182.	2.0	6
151	Platelets contain releasable coagulation factor IX antigen. Blood Coagulation and Fibrinolysis, 1993, 4, 905-910.	0.5	10
152	A Rapid Method to Isolate Platelets from Human Blood by Density Gradient Centrifugation. American Journal of Clinical Pathology, 1992, 98, 531-533.	0.4	46
153	Coagulation Factor IXa Binding to Activated Platelets and Platelet-Derived Microparticles: A Flow Cytometric Study. Thrombosis and Haemostasis, 1992, 68, 074-078.	1.8	81
154	Microplate coagulation assays. BioTechniques, 1992, 13, 430-3.	0.8	22
155	Role of gamma-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. Blood, 1992, 79, 398-405.	0.6	7
156	Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules.. Journal of Biological Chemistry, 1990, 265, 20907-20911.	1.6	15
157	Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain.. Journal of Biological Chemistry, 1990, 265, 10250-10254.	1.6	58
158	Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg").. Journal of Biological Chemistry, 1990, 265, 11982-11989.	1.6	44
159	Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg"). Journal of Biological Chemistry, 1990, 265, 11982-9.	1.6	28
160	Calcium ion binding to human and bovine factor X. Blood Coagulation and Fibrinolysis, 1990, 1, 633-40.	0.5	4
161	Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules. Journal of Biological Chemistry, 1990, 265, 20907-11.	1.6	10
162	Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. Journal of Biological Chemistry, 1990, 265, 10250-4.	1.6	38

#	Article	IF	Citations
163	Mechanism by which recombinant factor VIIa shortens the aPTT: Activation of factor X in the absence of tissue factor. Thrombosis Research, 1989, 56, 603-609.	0.8	79
164	Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo. Blood, 1989, 73, 1540-4.	0.6	11
165	Use of p-aminobenzamidine to monitor activation of trypsin-like serine proteases. Analytical Biochemistry, 1988, 172, 427-435.	1.1	26
166	Nontoxic Irreversible Inhibitors of Factors IXa, Xa, and Thrombin: Potential Therapeutic Agents for the in Vivo Regulation of Thrombin Generation and Activity. Annals of the New York Academy of Sciences, 1986, 485, 199-203.	1.8	0
167	p-Amidino esters as irreversible inhibitors of factors IXa, Xa, and thrombin. Biochemistry, 1986, 25, 4929-4935.	1.2	13
168	Comparison of lipid binding and kinetic properties of normal, variant, and .gamma.-carboxyglutamic acid modified human factor IX and factor IXa. Biochemistry, 1985, 24, 8064-8069.	1.2	36
169	Structural and Enzymatic Properties of Escherichia coli Glutamine Synthetase Subjected to Limited Proteolysis. Current Topics in Cellular Regulation, 1985, 27, 361-372.	9.6	6